Want to see HK:2530 full AI Analyst Report?
2530 Stock Chart & Stats
HK$0.59
--
Market closed
HK$0.59
--
Day’s Range― - ―
52-Week RangeHK$0.45 - HK$0.83
Previous CloseN/A
VolumeN/A
Average Volume (3M)43.20K
Market Cap
HK$740.00M
Enterprise ValueHK$177.02
Total Cash (Recent Filing)HK$401.65M
Total Debt (Recent Filing)HK$3.77M
Price to Earnings (P/E)89.5
Beta0.21
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.38%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,000,000,000
10 Day Avg. Volume61,600
30 Day Avg. Volume43,200
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)1.12
Price to Sales (P/S)3.00
P/FCF Ratio11.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet, Minimal LeverageVery low debt and substantial equity provide structural financial flexibility: the company can withstand revenue shocks, fund working capital or targeted investments without relying on external financing, and faces limited solvency risk over a multi-month horizon.
High Gross MarginsSustained ~66% gross margins indicate durable product-level profitability and potential pricing power. Even with weaker operating leverage, high gross margins give the company a structural cushion to absorb cost pressure or reinvest in marketing and R&D to rebuild scale.
Solid Cash Generation And ConversionOperating and free cash flow closely track earnings and comfortably cover reported profits, demonstrating reliable cash conversion. This persistent cash generation supports operational continuity, modest reinvestment, and flexibility in capital allocation despite recent earnings volatility.
Bears Say
Sharp Revenue And Profit Decline In 2025A one-year revenue drop of ~24% and collapse in net margin reflect a meaningful loss of scale or demand. Structural revenue weakness reduces operating leverage, limits reinvestment capacity and raises uncertainty about restoring prior profitability levels over the coming months.
Return On Equity CollapsedROE plunging to ~1% signals a sharp decline in capital efficiency and shareholder value creation. Persistently low returns make it harder to justify ongoing allocation of capital and may pressure strategic options if management cannot restore margins and profitable growth.
Declining Free Cash Flow TrendA ~37.5% drop in free cash flow and a downtrend from prior years reduce the firm's ability to self-fund investments or absorb shocks. Even with positive FCF in 2025, the decline indicates weakening operational momentum that could constrain strategic flexibility if it continues.
Numans Health Food Holdings Company Limited News
2530 FAQ
What was Numans Health Food Holdings Company Limited’s price range in the past 12 months?
Numans Health Food Holdings Company Limited lowest stock price was HK$0.45 and its highest was HK$0.83 in the past 12 months.
What is Numans Health Food Holdings Company Limited’s market cap?
Numans Health Food Holdings Company Limited’s market cap is HK$740.00M.
When is Numans Health Food Holdings Company Limited’s upcoming earnings report date?
Numans Health Food Holdings Company Limited’s upcoming earnings report date is Aug 28, 2026 which is in 9 days.
How were Numans Health Food Holdings Company Limited’s earnings last quarter?
Numans Health Food Holdings Company Limited released its earnings results on Apr 30, 2026. The company reported HK$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Numans Health Food Holdings Company Limited overvalued?
According to Wall Street analysts Numans Health Food Holdings Company Limited’s price is currently Overvalued.
Does Numans Health Food Holdings Company Limited pay dividends?
Numans Health Food Holdings Company Limited pays a Notavailable dividend of HK$0.025 which represents an annual dividend yield of 3.38%. See more information on Numans Health Food Holdings Company Limited dividends here
What is Numans Health Food Holdings Company Limited’s EPS estimate?
Numans Health Food Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Numans Health Food Holdings Company Limited have?
Numans Health Food Holdings Company Limited has 1,000,000,000 shares outstanding.
What happened to Numans Health Food Holdings Company Limited’s price movement after its last earnings report?
Numans Health Food Holdings Company Limited reported an EPS of HK$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Numans Health Food Holdings Company Limited?
Currently, no hedge funds are holding shares in HK:2530
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Numans Health Food Holdings Company Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
3.38%
Trailing 12-Months
Asset Growth
29.32%
Trailing 12-Months
Company Description
Numans Health Food Holdings Company Limited
Numans Health Food Holdings Company Limited focuses on the marketing, sale, and distribution of its Nemans-branded nutritional supplements across the People's Republic of China. Their extensive product range features algal oil docosahexaenoic acid (DHA), which supports brain and eye development in infants and children, and helps alleviate forgetfulness, anxiety, and postpartum depression in mothers. The company also offers probiotics, including solid drinks and lactic acid bacteria powders, to improve digestion and boost immunity for all ages. Other offerings include various vitamin and multi-nutrient products specifically formulated for pregnant women, infants, and children, as well as algal calcium and milk powders for diverse age groups. These products are distributed to consumers through both online platforms and traditional retail outlets. Established in Shanghai in 2002, Numans is a wholly-owned subsidiary of Far-East Fortune Management (China) Co., Ltd.
Technical Analysis
Besunyen Holdings Co. Ltd.
―
TS Wonders Holding Limited
―
Natural Food International Holding Ltd.
―
Vedan International (Holdings) Ltd.
―
China Starch Holdings Limited
―